GSK announced on Friday that the US Food and Drug Administration (FDA) has accepted its regulatory application for a prefilled syringe version of Shingrix, its recombinant zoster vaccine for ...

GSK) today announced that the US Food and Drug Administration (FDA) has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix (GSK's Recombinant Zoster ...

GSK (GSK) announced that the US Food and Drug Administration, FDA, has accepted for review the regulatory application of a prefilled syringe ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

GSK.L) announced Friday that the US Food and Drug Administration has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix, the Recombinant Zoster Vaccine ...

GSK plc, a global biopharma company, announced that the US Food and Drug Administration (FDA) has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix (GSK’s ...

The new prefilled syringe has the same composition but removes the need for reconstitution, providing a more convenient option for health care providers who administer vaccines. According to the ...

GSK managed to beat analysts’ revenue predictions ... driven once again by its shingles vaccine Shingrix and HIV therapies sold under the ViiV Healthcare joint venture. Shingrix grew 19% to ...

On the downside, GSK's COVID-19 therapy Xevudy (sotrovimab) saw a slump in demand, with sales falling to £500 million from £1.3 billion in the first quarter of 2022, and GSK is expecting the ...